Knowing the net value that companies, or whole sectors of the economy, bring is clearly important when considering economic and industrial policy. In this paper we estimate the economic contribution to the UK made by two British based, research intensive, pharmaceutical companies: AstraZeneca...

Most European Member States, particularly the former EU15 countries, have national systems providing universal access to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare, national governments have introduced mechanisms to regulate...

Looking at how well drugs work in routine clinical practice, rather than only in experimental randomised controlled clinical trials (RCTs), is increasingly seen as essential for a proper assessment of both net benefit (health gain minus harm and value (net benefit minus net cost). Establishing...

This paper reviews the economic case for patents and the potential for differential pricing to increase affordability of on-patent drugs in developing countries while preserving incentives for innovation. Differential pricing, based on Ramsey pricing principles, is the second best efficient way...

This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low income countries (MLICs), with robustness checks to other therapeutic categories and other...